Terms: = Skin cancer AND FIP1L1, DKFZp586K0717, 81608, ENSG00000145216, Q6UN15 AND Treatment
5 results:
1. Epidemiology, clinical picture and long-term outcomes of fip1l1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.
Rohmer J; Couteau-Chardon A; Trichereau J; Panel K; Gesquiere C; Ben Abdelali R; Bidet A; Bladé JS; Cayuela JM; Cony-Makhoul P; Cottin V; Delabesse E; Ebbo M; Fain O; Flandrin P; Galicier L; Godon C; Grardel N; Guffroy A; Hamidou M; Hunault M; Lengline E; Lhomme F; Lhermitte L; Machelart I; Mauvieux L; Mohr C; Mozicconacci MJ; Naguib D; Nicolini FE; Rey J; Rousselot P; Tavitian S; Terriou L; Lefèvre G; Preudhomme C; Kahn JE; Groh M;
Am J Hematol; 2020 Nov; 95(11):1314-1323. PubMed ID: 32720700
[TBL] [Abstract] [Full Text] [Related]
2. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract] [Full Text] [Related]
3. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
McPherson T; Cowen EW; McBurney E; Klion AD
Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
[TBL] [Abstract] [Full Text] [Related]
4. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract] [Full Text] [Related]
5. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract] [Full Text] [Related]
